Eculizumab in paroxysmal nocturnal hemoglobinuria

被引：0
作者：
Socie, Gerard [1 ]
Varoqueaux, Nathalie [2 ]
de Latour, Regis Peffault [1 ]
机构：
[1] Hop St Louis, INSERM, AP HP, Serv Hematol Greffe,U728, F-75010 Paris, France
[2] Alexion Pharma France, Direct Affaires Med, F-75008 Paris, France
来源：
M S-MEDECINE SCIENCES | 2009年 / 25卷 / 12期
关键词：
COMPLEMENT INHIBITOR ECULIZUMAB; PIG-A GENE; MICROPARTICLES; HEMOLYSIS; DISEASE;
D O I：
10.1051/medsci/200925121126
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Eculizumab in paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria is a rare acquired clonal of the hematopoietic stem cell due to acquired mutation of the PIG-A gene. This results in the lack of two GPI-anchored membrane proteins involved in the inhibition of complement attack, thus explaining red cells hemolysis. The development of an anti-C5 monoclonal antibody (eculizumab) had profoundly modified the treatment of the the hemolytic form of the disease.
引用
收藏
页码：1126 / 1129
页数：4
相关论文
共 18 条
[1]   Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria [J].
Brodsky, Robert A. ;
Young, Neal S. ;
Antonioli, Elisabetta ;
Risitano, Antonio M. ;
Schrezenmeier, Hubert ;
Schubert, Jorg ;
Gaya, Anna ;
Coyle, Luke ;
De Castro, Carlos ;
Fu, Chieh-Lin ;
Maciejewski, Jaroslaw P. ;
Bessler, Monica ;
Kroon, Henk-Andre ;
Rother, Russell P. ;
Hillmen, Peter .
BLOOD, 2008, 111 (04) :1840-1847
[2]   Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories [J].
de Latour, Regis Peffault ;
Mary, Jean Yves ;
Salanoubat, Celia ;
Terriou, Louis ;
Etienne, Gabriel ;
Mohty, Mohamad ;
Roth, Sophie ;
de Guibert, Sophie ;
Maury, Sebastien ;
Cahn, Jean Yves ;
Socie, Gerard .
BLOOD, 2008, 112 (08) :3099-3106
[3]   Cell-derived microparticles unveil their fibrinolytic and proteolytic function [J].
Doeuvre, Loic ;
Angles-Cano, Eduardo .
M S-MEDECINE SCIENCES, 2009, 25 (01) :37-44
[4]   Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria [J].
Hill, A ;
Hillmen, P ;
Richards, SJ ;
Elebute, D ;
Marsh, JC ;
Chan, J ;
Mojcik, CF ;
Rother, RP .
BLOOD, 2005, 106 (07) :2559-2565
[5]   Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria [J].
Hillmen, P ;
Hall, C ;
Marsh, JCW ;
Elebute, M ;
Bombara, MP ;
Petro, BE ;
Cullen, MJ ;
Richards, SJ ;
Rollins, SA ;
Mojcik, CF ;
Rother, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06) :552-559
[6]   Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria [J].
Hillmen, Peter ;
Muus, Petra ;
Duhrsen, Ulrich ;
Risitano, Antonio M. ;
Schubert, Jorg ;
Luzzatto, Lucio ;
Schrezenmeier, Hubert ;
Szer, Jeffrey ;
Brodsky, Robert A. ;
Hill, Anita ;
Socie, Gerard ;
Bessler, Monica ;
Rollins, Scott A. ;
Bell, Leonard ;
Rother, Russell P. ;
Young, Neal S. .
BLOOD, 2007, 110 (12) :4123-4128
[7]   The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria [J].
Hillmen, Peter ;
Young, Neal S. ;
Schubert, Joerg ;
Brodsky, Robert A. ;
Socie, Gerard ;
Muus, Petra ;
Roeth, Alexander ;
Szer, Jeffrey ;
Elebute, Modupe O. ;
Nakamura, Ryotaro ;
Browne, Paul ;
Risitano, Antonio M. ;
Hill, Anita ;
Schrezenmeier, Hubert ;
Fu, Chieh-Lin ;
Maciejewski, Jaroslaw ;
Rollins, Scott A. ;
Mojcik, Christopher F. ;
Rother, Russell P. ;
Luzzatto, Lucio .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (12) :1233-1243
[8]   Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia [J].
Hugel, B ;
Socié, G ;
Vu, T ;
Toti, F ;
Gluckman, E ;
Freyssinet, JM ;
Scrobohaci, ML .
BLOOD, 1999, 93 (10) :3451-3456
[9]  
Luzzatto L, 1996, Curr Opin Hematol, V3, P101
[10]   ABNORMALITIES OF PIG-A TRANSCRIPTS IN GRANULOCYTES FROM PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].
MIYATA, T ;
YAMADA, N ;
IIDA, Y ;
NISHIMURA, J ;
TAKEDA, J ;
KITANI, T ;
KINOSHITA, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) :249-255
12